Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned - Report - MDSpire
Advertisement
Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned
Clinical Report: Therapeutic Approaches Utilizing Cell and Extracellular Vesicles for AKI
Overview
Acute kidney injury (AKI) affects a significant portion of ICU patients and is linked to high mortality rates. Regenerative therapies using mesenchymal stromal cells (MSCs) and extracellular vesicles (EVs) have been explored for promoting renal recovery, though early clinical trials indicate limited efficacy.
Background
AKI is prevalent in critically ill patients, with current management strategies primarily focused on supportive care and renal replacement therapy (RRT). There is a need for therapies that can enhance renal repair and regeneration, as existing treatments do not address the underlying biological mechanisms of AKI.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
AKI affects up to 50% of ICU patients, contributing to high morbidity and mortality.
Current therapies do not modify the biological processes underlying AKI.
MSCs and MSC-derived EVs have shown potential in reducing inflammation and enhancing renal recovery in preclinical studies.
Early clinical trials have demonstrated safety but limited efficacy in AKI populations.
EV-based therapies offer advantages such as scalable manufacturing and easier integration into ICU workflows.
Future research should focus on phenotype-enriched enrollment and kidney-specific endpoints.
Clinical Implications
Clinicians should consider patient selection and timing of intervention when exploring the use of MSCs and EVs in AKI management.
Conclusion
Regenerative therapies for AKI require further investigation to determine their clinical application.
In a pooled analysis of two randomized crossover trials, reducing nightly sleep by about 1.5 hours for 6 weeks was associated with modest increases in body weight and waist circumference without measurable changes in body composition.
The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.
